LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma.
Loading...
Embargo End Date
ICR Authors
Authors
Jain, A
Zhang, J
Rabbitts, T
Zhang, J
Rabbitts, T
Document Type
Journal Article
Date
2017-01-05
Date Accepted
Abstract
Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
Citation
Clinics in oncology (Belmont, Calif.), 2017, 2 pp. 1183 - ?
DOI
Source Title
Publisher
ISSN
2474-1663
eISSN
2474-1663
Collections
Research Team
Chromosomal Translocations and Intracellular Antibody Therapeutics